Consensus on clinical diagnosis, treatment, and prevention of chemotherapy-induced neutropenia in China (2023 edition).
10.3760/cma.j.cn112152-20230224-00076
- VernacularTitle:肿瘤化疗导致的中性粒细胞减少诊治中国专家共识(2023版)
- Collective Name:China Anti-Cancer Association Tumor Clinical Chemotherapy Professional Committee;China Anti-Cancer Association Tumor Support Therapy Professional Committee
- Publication Type:Journal Article
- Keywords:
Chemotherapy-induced neutropenia;
Expert consensus;
Febrile neutropenia;
Malignant tumors;
Polyethylene glycol;
Recombinant human granulocyte colony stimulating factor
- MeSH:
Humans;
Granulocyte Colony-Stimulating Factor;
Consensus;
Neutropenia/prevention & control*;
Neoplasms/drug therapy*;
Antineoplastic Agents/adverse effects*;
Antineoplastic Combined Chemotherapy Protocols/adverse effects*
- From:
Chinese Journal of Oncology
2023;45(7):575-583
- CountryChina
- Language:Chinese
-
Abstract:
Chemotherapy-induced neutropenia (CIN) is a common hematological adverse events and dose-limiting toxicities of chemotherapy. CIN may lead to dose reduction and delay of chemotherapeutic agents, febrile neutropenia and severe infection, which results in increased treatment cost, reduced efficacy of chemotherapy, and even life-threatening morbidities. Assessment of risk of CIN, early detection of FN and infection, and proper prevention and treatment play a crucial role in reducing the occurrence of CIN-related morbidities, improving patient treatment safety and anticancer efficacy. Based on evidence and expert opinion, the expert committee of Chinese Anti-Cancer Association issued "the consensus on diagnosis and treatment of chemotherapy-induced neutropenia in China (2023 edition)", which is an update version of the 2019 edition, aiming to provide reference for the diagnosis and treatment of CIN for Chinese oncologists.
